Search results for "TF"

showing 10 items of 1652 documents

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

2019

Background The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the …

OncologyGermline0302 clinical medicineLoss of Function MutationSurgical oncologyOdds RatioPrevalenceMissense mutation030212 general & internal medicineAge of Onset10. No inequalityExomeEarly onset breast cancerAged 80 and overOvarian NeoplasmsBARD1 GeneHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030220 oncology & carcinogenesisFemaleTechnology PlatformsResearch ArticleAdultmedicine.medical_specialtyAdolescentUbiquitin-Protein Ligases610Breast Neoplasmslcsh:RC254-282Young Adult03 medical and health sciencesGermline mutationBreast cancerOvarian cancerInternal medicinemedicineBARD1HumansGenetic Predisposition to DiseaseGermline mutationsGenetic Association StudiesGerm-Line MutationAgedbusiness.industryTumor Suppressor ProteinsOdds ratiomedicine.diseaseConfidence intervalBARD1; Early onset breast cancer; Germline mutations; Ovarian cancerOvarian cancerbusiness
researchProduct

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

2016

The European Society for Medical Oncology (ESMO) is one of the leading societies of oncology professionals in the world. Approximately 30% of the 13 000 ESMO members are below the age of 40 and thus meet the society's definition of young oncologists (YOs). ESMO has identified the training and development of YOs as a priority and has therefore established a comprehensive career development programme. This includes a leadership development programme to help identify and develop the future leaders in oncology. Well-trained and highly motivated future generations of multidisciplinary oncologists are essential to ensure the optimal evolution of the field of oncology with the ultimate goal of pro…

Oncologymedicine.medical_specialtyCancer ResearchReviewFellowshipExecutive boardMultidisciplinary approachInternal medicineJournal ArticleMedicine15061507Leadership developmentbusiness.industryLeadership ProgrammeGénéralitésESMOTraining and developmentYoung OncologistsOncologyESMO; Fellowship; Leadership Programme; Preceptorship; Young OncologistsPreceptorshipPortfoliobusinessCareer developmentESMO; Fellowship; Leadership Programme; Preceptorship; Young Oncologists; Cancer Research; Oncology
researchProduct

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

2021

ABSTRACT Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-…

Oncologymedicine.medical_specialtyLIPI scoreLung Neoplasmsmedicine.medical_treatmentImmunologyThyroid Nuclear Factor 1Adenocarcinoma of Lungmedicine.disease_causeTTF1Internal medicinePD-L1Carcinoma Non-Small-Cell LungmedicineClinical endpointKRASImmunology and AllergyHumansLung cancerImmune Checkpoint InhibitorsRC254-282Retrospective StudiesOriginal Researchbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensprognostic factorsRetrospective cohort studyImmunotherapyRC581-607medicine.diseasePrognosisOncologyCohortbiology.proteinAdenocarcinomaKRASimmunotherapyImmunologic diseases. AllergybusinessAdenocarcinoma lung cancerBiomarkersResearch ArticleOncoimmunology
researchProduct

Pharmacogenetics of treatments for pancreatic cancer

2019

Introduction: Despite clinical efforts, pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The scarcity of effective therapies can be reflected by the lack of reliable biomarkers to adapt anticancer drugs prescription to tumors’ and patients’ features. Areas covered: Pharmacogenetics should provide the way to select patients who may benefit from a specific therapy that best matches individual and tumor genetic profile, but it has not yet led to gains in outcome. This review describes PDAC pharmacogenetics findings, critically reappraising studies on polymorphisms and -omics profiles correlated to response to gemcitabine, FOLFIRINOX, and nab-paclitaxel combinations, as well as l…

Oncologymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesFOLFIRINOXToxicology030226 pharmacology & pharmacyvalidated tests and clinical trial03 medical and health sciencesnab-paclitaxel0302 clinical medicinePancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorAnimalsHumansneoplasmspharmacogenetic studieNab-paclitaxelPharmacologyAntineoplastic Combined Chemotherapy Protocolbusiness.industryAnimalPatient SelectionPharmacogeneticfungigemcitabinePancreatic Neoplasmfood and beveragesGeneral MedicinePancreatic cancermedicine.diseasePrognosisSettore CHIM/08 - Chimica Farmaceuticadigestive system diseasesGemcitabinePancreatic NeoplasmsFOLFIRINOXPharmacogenetics030220 oncology & carcinogenesispromises and pitfalls of pharmacogenetic approachebusinessPharmacogeneticsmedicine.drugCarcinoma Pancreatic DuctalHumanExpert Opinion on Drug Metabolism and Toxicology
researchProduct

391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials

2021

Oncologymedicine.medical_specialtybusiness.industryColorectal cancerHematologymedicine.diseaseOutcome (game theory)Adjuvant TrialsMetforminPooled analysisOncologyInternal medicineDiabetes mellitusmedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

Virtual Clinical and Precision Medicine Tumor Boards-Cloud-Based Platform-Mediated Implementation of Multidisciplinary Reviews Among Oncology Centers…

2021

Background Multidisciplinary tumor boards play a pivotal role in the patient-centered clinical management and in the decision-making process to provide best evidence-based, diagnostic, and therapeutic care to patients with cancer. Among the barriers to achieve an efficient multidisciplinary tumor board, lack of time and geographical distance play a major role. Therefore, the elaboration of an efficient virtual multidisciplinary tumor board (VMTB) is a key point to successfully obtain an oncology team and implement a network among health professionals and institutions. This need is stronger than ever during the COVID-19 pandemic. Objective This paper presents a research protocol for an obse…

Oncologymedicine.medical_specialtytumorComputer scienceSettore MED/06 - Oncologia MedicaMultidisciplinary oncology consultationprecision medicinedigital healthSettore MED/42 - Igiene Generale E Applicatavirtual tumor boardPatient satisfactionplatformMultidisciplinary approachInternal medicinemedicineProtocolcancermultidisciplinary oncology consultationsmultidisciplinary communicationvirtual healthhealth servicesimplementationProtocol (science)multidisciplinary collaborationHealth Insurance Portability and Accountability ActCOVID-19General MedicinePrecision medicineDigital healthoncologycloud-basedHealth serviceCustomer satisfactionObservational studyJMIR research protocols
researchProduct

Ontological information system for the selection of technologies for the treatment and disposal of organic waste: engineering and educational aspects

2021

The article proves a problem of information processing in the field of the structuring of information and decision-making in environmental engineering, including education in this field. This article presents the ontology-information model that was used to systematize waste treatment equipment. The article presents the use of an ontological algorithm “Polyhedron” for engineers and teachers. The algorithm consists of integrating ontological solutions from abstract to specific. The proposed model consists of a general ontology of “waste treatment technologies selection”, “waste treatment equipment selection” and “Ontology for the analysis of scientific publications”. Users of the system can i…

Ontology-based approachEnvironmental managementCognitive IT platform polyhedronWaste treatment equipmentRisk analysis (engineering)WasteOntologyComputer scienceInformation systemSystematizationBiodegradable wasteSelection (genetic algorithm)DESALINATION AND WATER TREATMENT
researchProduct

Real Options Analysis (ROA)opens innovation: the biopharmaceutical case

2012

Open Innovation Real Options Analysis R&D Portfolio Biopharmacuetical industry
researchProduct

Diversification and performance in the mobile app market: The role of the platform ecosystem

2019

Abstract We examine the effect of app developers' product line diversification decision on their performance and shed light on whether the type of platform ecosystem (open versus closed) where they commercialize apps influences this effect. We compare the revenue performance of diversified and specialized developers in Apple's App Store and Google Play. We show that in the Apple's App Store (closed platform) diversified developers always display lower performance than their specialized counterparts. In Google Play (open platform) diversification is beneficial in categories where diversified developers have predominant market share, whereas it is detrimental in categories dominated by specia…

Open platformKnowledge management020209 energyInformationSystems_INFORMATIONSTORAGEANDRETRIEVALInformation technology02 engineering and technologyDiversification (marketing strategy)App storeManagement of Technology and Innovationmental disorders0502 economics and business0202 electrical engineering electronic engineering information engineeringRevenueEcosystemBusiness and International ManagementMarket shareMobile app marketApplied Psychologybusiness.industry05 social sciencesInformation technologySettore ING-IND/35 - Ingegneria Economico-GestionaleClosed platformPlatform ecosystemDiversificationbusiness050203 business & managementTechnological Forecasting and Social Change
researchProduct

Datortīklu mācību platformas pārveide

2021

Šis dokuments ir bakalaura darbs, kurš izstrādāts Latvijas Universitātes Datorikas fakultātes Datorzinātnes studiju programmas ietvaros. Dokumentā tiek veikti pētījumi par datortīklu un datorsistēmu mācību platformas ReSeLa pārveidi, kas iekļauj izpēti par populāru tiešsaistes mācību platformu iezīmēm un veicamo uzlabojumu tehnoloģiskajiem risinājumiem. Balstoties uz veiktajiem pētījumiem, tiek veikta sākotnējā jaunās platformas izstrāde, un dokumentā aprakstīta tās struktūra, API, izvēlētie risinājumi, trūkumi un nepieciešamie uzlabojumi, kā arī tiek aprakstīta un uzstādīta testa vide tās galvenajai ārējai saskarnei – OpenStack.

OpenStackDatorzinātneuzlabojumu risinājumiReSeLa pārveideTiešsaistes mācību platforma
researchProduct